What are the Challenges in Targeting Mitotic Catastrophe?
Targeting mitotic catastrophe in cancer therapy poses several challenges. Firstly, there is a risk of affecting normal cells, leading to toxicity and adverse effects. Secondly, the heterogeneity of tumors means that not all cancer cells may be equally susceptible to mitotic catastrophe. Lastly, understanding the complex signaling pathways involved in this process is still an area of active research, requiring precise targeting to avoid unintended consequences.
